Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

Experimental Hematology

Volumn 42, Issue 2, 2014, Pages

  Iancu Rubin, Camelia ^a   Mosoyan, Goar ^a   Glenn, Kelli ^b   Gordon, Ronald E ^a   Nichols, Gwen L ^b   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; RG 7112; RO 5045336; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; ENANTIOMER; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEGAKARYOBLAST; MEGAKARYOPOIESIS; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMIDAZOLINES; MALE; MICE; PLATELET COUNT; PROTO-ONCOGENE PROTEINS C-MDM2; THROMBOPOIESIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896702778     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.11.012     Document Type: Article

References (33)

1. Deutsch V.R., Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol 2013, 161:778-793.
2. Shahbazian D., Sznol J., Kluger H.M. Vertical pathway targeting in cancer therapy. Adv Pharmacol 2012, 65:1-26.
3. Ellis L., Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 2010, 3:2411-2469.
4. Shangary S., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009, 49:223-241.
5. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
6. Iancu-Rubin C., Gajzer D., Mosoyan G., Feller F., Mascarenhas J., Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 2012, 40:564-574.
7. Kitamura T., Inoue D. HDACI-induced thrombocytopenia is caused by its unexpected target. Exp Hematol 2012, 40:695-697.
8. Schoenwaelder S.M., Jarman K.E., Gardiner E.E., et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011, 118:1663-1674.
9. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13:23-31.
10. Vassilev L.T., Vu B.T., Graves B., et al. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
11. Tovar C., Rosinski J., Filipovic Z., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006, 103:1888-1893.
12. Kojima K., Konopleva M., Samudio I.J., et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005, 106:3150-3159.
13. Tovar C., Graves B., Packman K., et al. MDM2 Small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013, 73:2587-2597.
14. Andreeff M., Kevin R.K., Yee K., et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist, in acute leukemia. Blood 2012, 120. Abstract 675.
15. Andreeff M., Kojima K., Padmanabhan S., et al. A Multi-Center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). Blood 2010, 116. Abstract 657.
16. Beryzkina A., Nichols G., Reckner M., et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. JClin Oncol 2011, 29. Abstract 3039.
17. Ray-Coquard I., Blay J.Y., Italiano A., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13:1133-1140.
18. Ray-Coquard I.L., Blay J., Italiano A., et al. Neoadjuvant MDM2 antagonist RG7112 for well-differentiated liposarcomas (WW/DD LPS): A pharmacodynamic (PD) biomarker study. J Clinical Oncol 2011, 29. (suppl. abstract 10007b).
19. Bond G.L., Hu W., Levine A.J. MDM2 is a central node in the p53pathway: 12 years and counting. Curr Cancer Drug Targets 2005, 5:3-8.
20. Datta N.S., Long M.W. Modulation of MDM2/p53 and cyclin-activating kinase during the megakaryocyte differentiation of human erythroleukemia cells. Exp Hematol 2002, 30:158-165.
21. Baccini V., Roy L., Vitrat N., et al. Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes. Blood 2001, 98:3274-3282.
22. Fuhrken P.G., Apostolidis P.A., Lindsey S., Miller W.M., Papoutsakis E.T. Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis. J Biol Chem 2008, 283:15589-15600.
23. Apostolidis P.A., Woulfe D.S., Chavez M., Miller W.M., Papoutsakis E.T. Role of tumor suppressor p53 in megakaryopoiesis and platelet function. Exp Hematol 2012, 40:131-142.e4.
24. Apostolidis P.A., Lindsey S., Miller W.M., Papoutsakis E.T. Proposed megakaryocytic regulon of p53: the genes engaged to control cell cycle and apoptosis during megakaryocytic differentiation. Physiol Genomics 2012, 44:638-650.
25. McGowan K.A., Pang W.W., Bhardwaj R., et al. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood 2011, 118:3622-3633.
26. Robinson M.S., MacKie I.J., Machin S.J., Harrison P. Two colour analysis of reticulated platelets. Clin Lab Haematol 2000, 22:211-213.
27. Salvagno G.L., Montagnana M., Degan M., et al. Evaluation of platelet turnover by flow cytometry. Platelets 2006, 17:170-177.
28. Mattia G., Vulcano F., Milazzo L., et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002, 99:888-897.
29. Vu B., Wovkulich P., Pizzolato G., et al. Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett 2013, 4:466-469.
30. Iancu-Rubin C., Gajzer D., Tripodi J., et al. Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood 2011, 117:4580-4589.
31. Chagraoui H., Kassouf M., Banerjee S., et al. SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood 2011, 118:723-735.
32. Kuter D.J. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010, 47:243-248.
33. Currao M., Balduini C.L., Balduini A. High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes. PLoS One 2013, 8:e54723.